Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma

被引：91
作者：
Choi, Bryan D. [1 ,2 ]
Suryadevara, Carter M. [1 ]
Gedeon, Patrick C. [3 ]
Herndon, James E., II [4 ]
Sanchez-Perez, Luis [1 ]
Bigner, Darell D. [2 ,5 ]
Sampson, John H. [1 ,2 ,5 ]
机构：
[1] Duke Univ, Med Ctr, Dept Surg, Duke Brain Tumor Immunotherapy Program,Div Neuros, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
[3] Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA
[4] Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27710 USA
[5] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA
来源：
JOURNAL OF CLINICAL NEUROSCIENCE | 2014年 / 21卷 / 01期
基金：
美国国家卫生研究院;
关键词：
Central nervous system neoplasms; Epidermal growth factor receptor; Glioblastoma; Immunotherapy; T-lymphocytes; GROWTH-FACTOR RECEPTOR; T-CELLS; ADVERSE EVENT; SURVIVAL; THERAPY;
D O I：
10.1016/j.jocn.2013.03.012
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Chimeric antigen receptors (CAR)-transduced T cells hold great promise in the treatment of malignant disease. Here, we demonstrate that intracerebral injection with a human, epidermal growth factor receptor variant III (EGFRvIII)-specific, third generation CAR successfully treats glioma in mice. Importantly, these results endorse clinical translation of this CAR in patients with EGFRvIII-expressing brain tumors. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：189 / 190
页数：2
相关论文
共 9 条
  • [1] Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
    Brentjens, Renier
    Yeh, Raymond
    Bernal, Yvette
    Riviere, Isabelle
    Sadelain, Michel
    [J]. MOLECULAR THERAPY, 2010, 18 (04) : 666 - 668
  • [2] Genetically engineered T cells to target EGFRvIII expressing glioblastoma
    Bullain, Szofia S.
    Sahin, Ayguen
    Szentirmai, Oszkar
    Sanchez, Carlos
    Lin, Ning
    Baratta, Elizabeth
    Waterman, Peter
    Weissleder, Ralph
    Mulligan, Richard C.
    Carter, Bob S.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2009, 94 (03) : 373 - 382
  • [3] EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma
    Choi, Bryan D.
    Archer, Gary E.
    Mitchell, Duane A.
    Heimberger, Amy B.
    McLendon, Roger E.
    Bigner, Darell D.
    Sampson, John H.
    [J]. BRAIN PATHOLOGY, 2009, 19 (04) : 713 - 723
  • [4] Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
    Milone, Michael C.
    Fish, Jonathan D.
    Carpenito, Carmine
    Carroll, Richard G.
    Binder, Gwendolyn K.
    Teachey, David
    Samanta, Minu
    Lakhal, Mehdi
    Gloss, Brian
    Danet-Desnoyers, Gwenn
    Campana, Dario
    Riley, James L.
    Grupp, Stephan A.
    June, Carl H.
    [J]. MOLECULAR THERAPY, 2009, 17 (08) : 1453 - 1464
  • [5] Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma
    Morgan, Richard A.
    Johnson, Laura A.
    Davis, Jeremy L.
    Zheng, Zhili
    Woolard, Kevin D.
    Reap, Elizabeth A.
    Feldman, Steven A.
    Chinnasamy, Nachimuthu
    Kuan, Chien-Tsun
    Song, Hua
    Zhang, Wei
    Fine, Howard A.
    Rosenberg, Steven A.
    [J]. HUMAN GENE THERAPY, 2012, 23 (10) : 1043 - 1053
  • [6] Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
    Morgan, Richard A.
    Yang, James C.
    Kitano, Mio
    Dudley, Mark E.
    Laurencot, Carolyn M.
    Rosenberg, Steven A.
    [J]. MOLECULAR THERAPY, 2010, 18 (04) : 843 - 851
  • [7] A MUTANT EPIDERMAL GROWTH-FACTOR RECEPTOR COMMON IN HUMAN GLIOMA CONFERS ENHANCED TUMORIGENICITY
    NISHIKAWA, R
    JI, XD
    HARMON, RC
    LAZAR, CS
    GILL, GN
    CAVENEE, WK
    HUANG, HJS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (16) : 7727 - 7731
  • [8] Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen
    Ohno, Masasuke
    Natsume, Atsushi
    Iwami, Ken-ichiro
    Iwamizu, Hidetaka
    Noritake, Kana
    Ito, Daiki
    Toi, Yuki
    Ito, Motokazu
    Motomura, Kazuya
    Yoshida, Jun
    Yoshikawa, Kazuhiro
    Wakabayashi, Toshihiko
    [J]. CANCER SCIENCE, 2010, 101 (12) : 2518 - 2524
  • [9] Long-term survival of patients with glioblastoma multiforme (GBM)
    Smoll, Nicolas R.
    Schaller, Karl
    Gautschi, Oliver P.
    [J]. JOURNAL OF CLINICAL NEUROSCIENCE, 2013, 20 (05) : 670 - 675
1